Fibrocell Reports Fourth Quarter and Full Year 2015 Financial Results and Operational Highlights

Fibrocell Science, Inc. (NASDAQ:FCSC) announced its financial results for the fourth quarter and year ended December 31, 2015 and operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EST.
David Pernock, Chairman and Chief Executive Officer commented:

Fibrocell’s progress across our pipeline of personalized biologics was significant in 2015, and positions us well to extend this momentum into 2016 and beyond. In the first half of 2016 we plan to achieve several major milestones including initiating human clinical trials for FCX-007, our gene-therapy product candidate for the treatment of recessive dystrophic epidermolysis bullosa, as well as reporting Phase II clinical data for azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. In addition, we expect to continue pre-clinical studies for FCX-013, our gene-therapy product candidate for the treatment of linear scleroderma.

Click here to view the full press release.